Potential for Cripto-1 in defining stem cell-like characteristics in human malignant melanoma

The diagnosis of melanoma is becoming ever more frequent. Although surgical excision of early lesions is associated with relatively significant high cure rates, treatment modalities are largely unsuccessful for advanced disease. Characteristics such as cellular heterogeneity and plasticity, expression of certain molecules such as the multidrug resistance protein-1 (MDR1) or the aberrant expression of embryonic signaling molecules and morphogens like Nodal, important for self renewal and pluripotency, suggest that a stem cell-like population may reside in aggressive melanomas. This perspective focuses on preliminary findings obtained in our laboratory which indicate that the expression of the Nodal co-receptor, Cripto-1, in a subset of malignant melanoma cells may be exploited to identify possible melanoma stem cells (MSC). In fact, the use of anti-Cripto-1 antibodies to cell sort Cripto-1-positive cells in the metastatic melanoma cell line C8161 has identified a slow growing, sphere forming subpopulation that expresses increased levels of Oct4, Nanog and MDR1. If current in vivo studies confirm the self renewal and tumorigenic characteristics of these cells, the expression of Cripto-1 may represent a useful marker to identify cancer stem cells in melanoma, and possibly other aggressive tumors as well.

[1]  Gideon Rechavi,et al.  MDR1 expression identifies human melanoma stem cells. , 2008, Biochemical and biophysical research communications.

[2]  M. Hendrix,et al.  Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells , 2008, Proceedings of the National Academy of Sciences.

[3]  J. Belo,et al.  Cripto-independent Nodal signaling promotes positioning of the A-P axis in the early mouse embryo. , 2008, Developmental biology.

[4]  M. Katoh,et al.  WNT Signaling Pathway and Stem Cell Signaling Network , 2007, Clinical Cancer Research.

[5]  A. Feinberg,et al.  The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells , 2007, Journal of cellular biochemistry.

[6]  M. Hendrix,et al.  Exploiting the Convergence of Embryonic and Tumorigenic Signaling Pathways to Develop New Therapeutic Targets , 2007, Stem Cell Reviews.

[7]  K. Mallikarjuna,et al.  Cripto-1 expression in uveal melanoma: an immunohistochemical study. , 2007, Experimental eye research.

[8]  Mary J. C. Hendrix,et al.  Reprogramming metastatic tumour cells with embryonic microenvironments , 2007, Nature Reviews Cancer.

[9]  V. Pantesco,et al.  A Meta‐Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web‐Based Expression Atlas , 2007, Stem cells.

[10]  Caterina A M La Porta,et al.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. , 2007, European journal of cancer.

[11]  T. Einarson,et al.  Treatments for metastatic melanoma: synthesis of evidence from randomized trials. , 2006, Cancer treatment reviews.

[12]  M. Hendrix,et al.  Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness , 2006, Nature Medicine.

[13]  L. Hyslop,et al.  The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. , 2006, Human molecular genetics.

[14]  K. Burrage,et al.  Stochastic models for regulatory networks of the genetic toggle switch. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Hendrix,et al.  Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  X. Chen,et al.  The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells , 2006, Nature Genetics.

[17]  M. Hendrix,et al.  A Three‐Dimensional Model to Study the Epigenetic Effects Induced by the Microenvironment of Human Embryonic Stem Cells , 2006, Stem cells.

[18]  A. Meng,et al.  Nodal signals pattern vertebrate embryos , 2006, Cellular and Molecular Life Sciences CMLS.

[19]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[20]  David Salomon,et al.  Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis , 2005, Oncogene.

[21]  R. Pedersen,et al.  Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. , 2004, Developmental biology.

[22]  Michael M Shen,et al.  Two Modes by which Lefty Proteins Inhibit Nodal Signaling , 2004, Current Biology.

[23]  A. Schier Nodal signaling in vertebrate development. , 2003, Annual review of cell and developmental biology.

[24]  Chenbei Chang,et al.  Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. , 2003, Genes & development.

[25]  M. Hendrix,et al.  Angiogenesis: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma , 2003, Nature Reviews Cancer.

[26]  M. Hendrix,et al.  Molecular plasticity of human melanoma cells , 2003, Oncogene.

[27]  H. Schöler,et al.  Stem cell pluripotency and transcription factor Oct4 , 2002, Cell Research.

[28]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[29]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Talbot,et al.  Nodal signaling patterns the organizer. , 2000, Development.

[32]  A. Schier,et al.  Nodal signalling in vertebrate development , 2000, Nature.

[33]  T. Bouwmeester,et al.  The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals , 1999, Nature.

[34]  R. Harland,et al.  The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. , 1998, Molecular cell.

[35]  J. Collignon,et al.  Relationship between asymmetric nodal expression and the direction of embryonic turning , 1996, Nature.

[36]  R. Harland,et al.  A nodal-related gene defines a physical and functional domain within the Spemann organizer , 1995, Cell.

[37]  M. N. Epstein,et al.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.

[38]  Claus Garbe,et al.  Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. , 2008, Advances in experimental medicine and biology.

[39]  Guangjin Pan,et al.  Nanog and transcriptional networks in embryonic stem cell pluripotency , 2007, Cell Research.

[40]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[41]  Raymond L. Barnhill,et al.  Long-Term Results of a Prospective Surgical Trial Comparing 2 cm vs. 4 cm Excision Margins for 740 Patients With 1–4 mm Melanomas , 2001, Annals of Surgical Oncology.

[42]  A. Sober,et al.  Ultraviolet radiation and malignant melanoma. , 1998, Clinics in dermatology.